The favorable effect of regional citrate anticoagulation on interleukin-1β release is dissociated from both coagulation and complement activation

Journal of Nephrology

Volumn 17, Issue 6, 2004, Pages 819-825

  Gabutti, Luca ^a   Ferrari, Nicola ^a   Mombelli, Giorgio ^a   Keller, Franco ^b   Marone, Claudio ^c  

^a Ospedale La Carita   (Switzerland)

^b REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^c OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Coagulation; Complement C3a; Hemodialysis; Interleukin 1 beta; Regional citrate anticoagulation

Indexed keywords

CITRATE TRISODIUM; COMPLEMENT COMPONENT C3A; D DIMER; FIBRINOPEPTIDE A; HEPARIN; INTERLEUKIN 1BETA; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; CITRIC ACID; INTERLEUKIN 1; PEPTIDE FRAGMENT; PEPTIDE HYDROLASE; PROTEIN PRECURSOR; PROTHROMBIN FRAGMENT 1; PROTHROMBIN FRAGMENT 2;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BIOCOMPATIBILITY; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE PRODUCTION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; BLOOD; BLOOD CLOTTING; CHRONIC KIDNEY FAILURE; DRUG EFFECT; METABOLISM; RENAL REPLACEMENT THERAPY;

ANTICOAGULANTS; ANTITHROMBIN III; BLOOD COAGULATION; CITRATES; COMPLEMENT ACTIVATION; COMPLEMENT C3A; FIBRINOPEPTIDE A; HUMANS; INTERLEUKIN-1; KIDNEY FAILURE, CHRONIC; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PROTEIN PRECURSORS; PROTHROMBIN; RENAL DIALYSIS; SINGLE-BLIND METHOD;

EID: 16644392433     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Cheung AK, Faezi-Jenkin B, Leypoldt JK. Effect of thrombosis on complement activation and neutrophil degranulation during in vitro hemodialysis. J Am Soc Nephrol 1994; 5: 110-5.
2. Gabutti L, Marone C, Colucci G, Duchini F, Schönholzer C. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med 2002; 28: 1419-25.
3. Böhler J, Schollmeyer P, Dressel B, Dobos G, Höl W. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol 1996; 7: 234-41.
4. Janssen MJ, Huijgens PC, Bouman AA, Oe PL, Van der Meulen J. Citrate anticoagulation and divalent cations in hemodialysis. Blood Purif 1994; 12: 308-16.
5. Hofbauer R, Moser D, Frass M, Oberbauer R, Kaye AD, Wagner O, Kapiotis S, Druml W. Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int 1999; 56: 1578-83.
6. Bos JC, Grooteman MP, Van Houte AJ, Schoorl M, Van Limbeek J, Nube MJ. Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Nephrol Dial Transplant 1997; 12: 1387-93.
7. Dhondth A, Vanholder R, Waterloos MA, Glorieux G, De Smet R, Lameire N. Citrate anticoagulation does not correct cuprophane bioincompatibility as evaluated by the expression of leukocyte surface molecules. Nephrol Dial Transplant 1998; 13: 1752-8.
8. Chenoweth DE. Complement activation during hemodialysis: clinical observations, proposed mechanisms and theoretical implications. Artif Organs 1984; 8: 281-90.
9. Haeffner-Cavaillon N, Kazatchkine MD. Induction of interleukin 1 synthesis. A new criterion of biocompatibility of extracorporeal circuits. Presse Med 1991; 20: 797-801.
10. Lazarus JM, Owen WF. Role of bioincompatibility in dialysis morbidity and mortality. Am J Kidney Dis 1994; 24: 1019-32.
11. Gesualdo L, Pertosa G, Grandaliano G, Schena F. Cytokines and biocompatibility. Nephrol Dial Transplant 1998; 13: 1622-6.
12. Dhondt A, Vanholder R, Tielemans C, Glorieux G, Waterloos MA, De Smet R, Lameire N. Effect of regional citrate anticoagulation on leukopenia, complement activation and expression of leukocyte surface molecules during hemodialysis with unmodified cellulose membranes. Nephron 2000; 85: 334-42.
13. Nossel HL, Yudelman I, Canfield RE, Butler VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53.
14. Bartels PC, Schoorl M, Wiering JG, Nube MJ. Activation of coagulation during treatment with hemodialysis. Scand J Clin Lab Invest 2000; 60: 283-90.
15. Salem M, Ivanovich P, Mujais S. Biocompatibility of dialysis membranes. Contrib Nephrol 1993; 103: 55-64.
16. Lin YF, Chang DM, Shaio MF, Lu KC, Chyr SH, Li BL, Sheih SD. Cytokine production during hemodialysis: effect of dialytic membrane and complement activation. Am J Nephrol 1996; 16: 293-9.
17. Wiegmann TB, McDougall ML, Diederich DA. Dialysis leukopenia, hypoxemia and anaphylatoxin formation: effect of membrane, bath and citrate anticoagulation. Am J Kidney Dis 1988; 11: 418-24.
18. Böhler J, Donauer J, Birmelin M, Schollmeyer PJ, Hörl WH. Mediators of complement-independent granulocyte activation during haemodialysis: role of calcium, prostaglandins and leukotriens. Nephrol Dial Transplant 1993; 8: 1359-65.
19. McLeod BC, Viernes A, Sassetti RJ. Complement activation by plasma separator membranes. Transfusion 1983; 23: 143-7.
20. Cappelli G, DiFelice A, Perrone S, Ballestri M, Bonucchi D, Savazzi AM, Ciuffreda A, Lusvarghi E. Which level of cytokine production is critical in haemodialysis? Nephrol Dial Transplant 1998; 13: 55-60.
21. Dinarello CA. Interleukin-1 and interleukin-1 receptor antagonist production during haemodialysis: which cytokine is a surrogate marker for dialysis-related complications? Nephrol Dial Transplant 1995; 10 (suppl 3): S25-8.
22. Omokawa S, Malchesky PS, Yamashita M, Goldcamp JB, Nosé Y. Anticoagulant and membrane effects on humoral and cellular changes during plasmapheresis. ASAIO Trans 1988; 34: 404-9.
23. Schindler R, Linnenweber S, Schulze M, Oppermann M, Dinarello C, Shaldon S, Koch KM. Gene expression of interleukin-1 beta during hemodialysis. Kidney Int 1993; 43: 712-21.
24. Pertosa G, Grandaliano G, Gesualdo L, Schena FP. Clinical relevance of cytokine production in hemodialysis. Kidney Int 2000; 58 (suppl): S104-11.
25. Weiler JM, Yurt RW, Fearon DT, Austen KF. Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J Exp Med 1978; 147: 409-21.
26. Boackle RJ, Caughman GB, Vesely J, Medgyesi G, Fudenberg HH. Potentiation of factor H by heparin: a rate limiting mechanism for inhibition of the alternative complement pathway. Mol Immunol 1983; 20: 1157-64.